PF-08653944

Berobenatide (PF-08653944, formerly MET-097i) is Pfizer's Phase 3 injectable weight-loss drug, acquired from Metsera in a deal completed November 2025 after a contested bidding process with Novo Nordisk. The final terms were $65.60 per share in cash (enterprise value ~$7.0B) plus a contingent value right of up to $20.65 per share, bringing headline deal value to roughly $10B; that is nearly double the ~$4.9B enterprise value of the original September offer, a jump directly attributable to Novo's counter-bid [1]. Berobenatide is a biased GLP-1 receptor agonist peptide engineered for an ultra-long half-life of roughly 15 days, positioned for once-monthly maintenance dosing across the VESPER program [2][3][15]. Pfizer moved it straight into Phase 3 with three trials totaling more than 5,500 patients across obesity and obesity with type 2 diabetes [2][3][4]. The commercial thesis is straightforward: monthly maintenance dosing that competes with weekly Wegovy and Zepbound on convenience, potentially closing the compliance gap in the GLP-1 category where a majority of commercial patients discontinue within twelve months. For Pfizer, this is the flagship obesity asset after the oral GLP-1 danuglipron failed on liver signals in 2025 [7].

Novel compound, never approved for any indication. Currently in Phase 3 development via Pfizer's VESPER program. No breakthrough therapy, fast track, or other FDA designations have been publicly disclosed. Three Phase 3 trials are active: NCT07311850 (n=3,578, once-weekly berobenatide in overweight or obese adults, active not recruiting) [2], NCT07400653 (n=1,044, obesity plus type 2 diabetes, active not recruiting) [4], and NCT07595549 (n=954, obesity, recruiting) [3]. A Phase 2 combination study, SOLIS-1 (NCT07575932, n=872), pairs berobenatide with PF-08653945, a companion amylin analog acquired in the same Metsera transaction [5]. A dedicated Phase 1 gastric emptying study (NCT07508241) is also running to characterize GI transit effects. The predecessor Phase 2b monotherapy trial (VESPER-1) reported topline results in 2025 under the Metsera-era compound name MET-097i, showing 14.1% placebo-subtracted weight loss at 28 weeks; that dataset is the basis for the entire Phase 3 program but is not currently linked in BioCosm's DB to this Pfizer-era node [14]. Pfizer completed the Metsera acquisition in November 2025 [1]. Expected primary readouts on the lead once-weekly Phase 3 fall in the 2027 window based on trial durations. No BLA submission target has been disclosed on Pfizer earnings calls [6].

GLP-1 is a gut hormone released after meals. It nudges the pancreas to release insulin, signals the brain to feel full, and slows the rate at which the stomach empties. Approved drugs that mimic GLP-1, including semaglutide (Wegovy, Ozempic) and the dual GIP/GLP-1 agonist tirzepatide (Zepbound, Mounjaro), reproduce that signal for days at a time. Berobenatide does two things differently. First, it is engineered for an ultra-long half-life of roughly 360 hours (~15 days) via a lipidation approach Pfizer describes as 'halo-lipidation,' a fatty-acid-based modification that binds serum albumin at a structurally distinct site relative to semaglutide's fatty-acid tether, keeping the peptide in circulation long enough to support monthly maintenance dosing rather than the weekly schedule required for semaglutide [15]. Second, it is described as a fully-biased GLP-1 receptor agonist: it preferentially activates the cAMP signaling arm downstream of the receptor (the pathway responsible for insulin release and satiety) while minimizing beta-arrestin recruitment. Preclinical work suggests beta-arrestin recruitment can drive receptor desensitization, and there is a preclinical hypothesis (mechanistically debated) that it contributes to the GI adverse-event profile of the class, though nausea in humans is thought to be primarily mediated by central GLP-1 receptors in the area postrema rather than peripheral beta-arrestin signaling. Whether biased agonism translates into better human GI tolerability remains unproven and is a key secondary endpoint to watch [7]. The companion asset PF-08653945 is an amylin analog: amylin is a pancreatic beta-cell hormone co-secreted with insulin that suppresses glucagon, slows gastric emptying, and produces satiety through a distinct receptor family; combining a GLP-1 agonist with an amylin analog stacks two independent satiety pathways and is the same combination logic Novo is pursuing with CagriSema. The genetic and pharmacologic case for hitting GLP1R is airtight. Five approved GLP-1 or GLP-1/GIP drugs have generated tens of billions in combined 2024 revenue between Novo Nordisk and Lilly, and human genetic data via Open Targets shows the strongest links of GLP1R to type 2 diabetes and obesity [8][9].

The VESPER Phase 3 package is built around three parallel monotherapy studies. NCT07311850 is the largest at 3,578 participants, testing once-weekly berobenatide against placebo in adults with overweight or obesity without diabetes, primary endpoint is percent change from baseline in body weight at 68 or 72 weeks [2]. NCT07400653 (n=1,044) enrolls a similar population but with type 2 diabetes, same primary endpoint [4]. NCT07595549 (n=954) is a third obesity trial still recruiting as of Q3 2026 [3]. All three use placebo comparator arms rather than head-to-head against semaglutide or tirzepatide, which is standard for the obesity space but leaves payers to compare across trials rather than within one. The Phase 2 SOLIS-1 combination trial (NCT07575932, n=872) tests berobenatide plus the companion amylin analog PF-08653945 against monotherapy, which is where the more interesting efficacy signal will land [5]. Enrollment across the four active trials totals roughly 6,448 patients, an aggressive commitment consistent with Pfizer's stated goal of a competitive launch package. Notably absent is a dedicated cardiovascular outcomes trial, which will matter for the SELECT-style label expansion Novo already secured with semaglutide [10]. Also unaddressed publicly: the device and delivery format for a monthly injectable. Autoinjector readiness, cold-chain requirements, and patient willingness to accept a larger single dose versus a familiar weekly pen are all execution-level questions that will surface at launch but are not yet disclosed.

Our model estimates a 56% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 66%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual, larger-than-typical enrollment for this phase, and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the largest and most concrete. Semaglutide 2.4mg produced roughly 15% mean weight loss at 68 weeks in STEP 1 [12]; tirzepatide 15mg produced 20-22% at 72 weeks in SURMOUNT-1 [13]. Metsera's Phase 2b VESPER-1 trial of MET-097i (now berobenatide) reported 14.1% placebo-subtracted weight loss at 28 weeks, competitive with semaglutide but well short of tirzepatide [14]. If Phase 3 lands in that range, berobenatide launches as the number-three mono-agonist in a market that is already moving to dual and triple agonists like retatrutide. Safety risk is largely class-standard: nausea, vomiting, potential pancreatitis, thyroid C-cell tumor signal in rodents that appears on all GLP-1 labels. The biased-agonism thesis predicts better GI tolerability, but that has not been demonstrated in a large trial. Execution risk is low given Pfizer's scale, though a monthly injection introduces device and cold-chain questions that a familiar weekly pen does not. The real threat is commercial. Even at parity with semaglutide on efficacy and superior on dosing frequency, payers may not reimburse a monthly premium injection when Lilly is scaling manufacturing aggressively and generic semaglutide is on a jurisdiction-dependent timeline. Canadian semaglutide compound patents lapsed in early 2026 and generics are entering there; in India, Novo's compound patent expired in March 2026 and multiple generics are in late-stage development; US expiry is generally cited around 2031-2032 on the compound patent but Novo holds a portfolio of formulation and use patents that are actively contested and may extend exclusivity in some indications [16]. Danuglipron's discontinuation in 2025 on hepatotoxicity is the recent reminder that Pfizer will not push through a drug that fails to clear a competitive bar [7].

Watch, high signal. Pfizer paid roughly $10B headline value (~$7.0B upfront enterprise value plus up to ~$3B in CVRs) to acquire Metsera specifically for this asset [1], after starting at ~$4.9B and being forced up by Novo's counter-bid. That is the strongest possible internal-conviction signal on the Phase 2 dataset, and the deal escalation itself is informative: Novo, which knows this space better than any other pharma, judged the asset worth a public fight. The next major signal is the once-weekly Phase 3 readout on NCT07311850, expected in the 2027 window, which will show whether berobenatide can match or beat semaglutide on weight loss with a superior dosing frequency [2]. The earlier and more asymmetric signal is the SOLIS-1 combination readout (berobenatide plus amylin analog PF-08653945). If that combo lands in tirzepatide-class efficacy territory, the program repositions from a me-too monthly GLP-1 into a genuine competitive threat to Lilly. Pfizer's entire obesity strategy hinges on berobenatide after danuglipron's failure [7], so expect aggressive Phase 3 execution and increasingly specific guidance on quarterly earnings calls. Check back after ADA 2027 and any preliminary VESPER data disclosure, and monitor Pfizer's earnings commentary each quarter for enrollment completion milestones and any interim safety signals.